$MNK While this is a very risky bet, I still think there is some hope for this company. CMS verdict should be favorable considering the supporting documentation Mallinckrodt has proving CMS violated its own policy in regards to Acthar’s base AMP. We have 4 new drugs that will be released next year and management seems optimistic on a global opioid settlement. Staying long MNK.
  • 11